Rat models of human T-cell leukemia virus type 1 (HTLV-1)-related
diseases such as adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis have been reported. However, these models do not completely reproduce human diseases partly because
HTLV-1 replicates poorly in rats. We investigated here the possible
reason for this. We found that the activity of Rex in rat cells is
quite low compared to that in human cells. As Rex function depends
largely on the CRM1 protein, whose human type (human CRM1 [hCRM1])
directly binds to Rex and exports it from the nucleus to the cytoplasm,
we assessed whether rat CRM1 (rCRM1) could act as well as hCRM1 as a
cofactor for Rex activity. We first cloned a cDNA encoding rCRM1 and
found that both rCRM1 and hCRM1 could bind to and export Rex protein to
the cytoplasm with similar efficiencies. However, unlike hCRM1, rCRM1
could hardly support Rex function because of its poor ability in
inducing the Rex-Rex interaction required for RNA export into the
cytoplasm. These observations suggest that the poor ability of rCRM1 to
act as a cofactor for Rex function may be responsible for the poor replication of HTLV-1 in rats.
 |
INTRODUCTION |
Human T-cell leukemia virus
type 1 (HTLV-1) is a causative agent of both adult T-cell leukemia
(ATL), which is an aggressive malignancy of T cells (17,
23), and the chronic neurodegenerative disorder
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
(22, 38). HTLV-1 belongs to a group of complex
retroviruses that encode transactivator proteins for their gene
expression. In HTLV-1, these transactivator proteins include Tax
protein, which activates its own viral and cellular transcription
(51), and Rex protein, a posttranscriptional regulator
that is required for the expression of unspliced and incompletely
spliced viral mRNAs that encode Gag and Env proteins, respectively
(6, 15, 20). These proteins are therefore essential for
viral replication.
Rex is a 27-kDa phosphoprotein that shuttles between the nucleus and
the cytoplasm (3, 26). In the nucleus, Rex binds directly
and specifically to the highly structured cis-acting Rex
response element (RxRE), which is encoded by sequences within the 3'
long terminal repeat of HTLV-1 (1, 42). The arginine-rich basic domain comprising amino acids (aa) 1 to 19 of the 189-aa Rex
protein has been shown to mediate its binding to the RxRE (1, 4,
10, 12). This region also serves as a nuclear/nucleolar localization signal (5, 29, 36, 41, 44).
Another important Rex domain is a leucine-rich region spanning aa 81 to
94 (3, 26), which functions as a nuclear export signal
(NES). This domain binds directly to human CRM1 (hCRM1; exportin 1, XPO1) (11), a member of the importin
family, in cooperation with a GTP-bound form of small G-protein Ran (Ran-GTP). It
is well known that Ran-GTP is located in the nucleus, while a GDP-bound
form of Ran is in the cytoplasm. This gradient of Ran across the
nuclear envelope is a key in the decision of directionality of the
transport machine. hCRM1 has been shown to be a component of the
cellular machinery involved in the protein export of various leucine-rich NES-bearing proteins (7, 9, 30, 35, 39, 45).
The interaction of Rex, hCRM1, Ran-GTP, and the Rex target, viral
mRNA, generates the export complex that is then transported to
the cytoplasm.
Rex has a third domain that maps to aa 57 to 66 and 106 to 124 and that
mediates Rex multimerization (2, 14, 50). Multimerization of Rex on the target viral mRNA is critical for Rex-mediated mRNA transport (1, 4, 10, 12) although the Rex protein itself does not require multimerization to exit the nucleus (14).
It has been generally agreed that the ability of the Rex protein to
form a homodimer, at least, is required for Rex multimerization on its
cognate RNA (2). Our previous data showed that hCRM1 is
involved in the homodimer formation of Rex (11). Thus,
hCRM1 participates both in the export of the target viral mRNA complex and the multimerization of Rex. hCRM1 could therefore be considered to
be the most critical cofactor guiding Rex function.
Appropriate animal models of HTLV-1 infection would allow us to analyze
the pathogenesis and oncogenesis of HTLV-1-associated diseases, which
could lead to the development of therapeutic and preventative measures.
HTLV-1 has been known to be able to infect experimental animals such as
monkeys, rabbits, and rats. Monkey and rabbit models have been used in
vaccine development and to study mother-to-child transmission caused by
breast feeding and in some cases ATL (19, 43, 48, 49). The
utility of these models is limited, however, because of the difficulty
in dealing with a number of these animals and the lack of inbred
strains. Consequently, it would be more convenient to use small-animal models, in particular mouse and rat models, because their inbred strains are well characterized and can be genetically manipulated. With
regard to mouse models, although attempts to infect mice with HTLV-1
have been reported, the infection was limited and could be detected
only with PCR that measured the integrated genomes of HTLV-1
(6). Rat models, on the other hand, have been extensively developed to study HTLV-1-associated diseases. For example, the HAM/TSP-like disease models for rats of the WKA strain have been used
to analyze the pathogenic mechanisms of this disease (21, 32), although further study is required to determine its
similarity to the corresponding human disease. Recently, in attempts to
establish rat models for lymphoproliferative disease and the
seronegative HTLV-1 carrier state, various syngeneic
HTLV-1-immortalized cell lines and administration routes in
immunocompetent and T-cell-deficient nude rats were examined. The nude
rats receiving syngeneic HTLV-1-producing cells developed ATL-like
disease (25, 28, 37). However, although these rat models
have certainly allowed us to understand HTLV-1-associated diseases
better, the ATL-like disease in these models could be induced in only
T-cell-deficient nude rats. This is unlike the human situation, in
which patients with ATL have competent immune systems prior to
disease development. Thus, to better understand the mechanism by which
ATL and HAM/TSP develop, a better rat model is required. Developing
such models has, however, been hampered by the poor replication of
HTLV-1 in rats.
HTLV-1 has been reported to be able to infect a number of rat cells,
which indicates that the rat cells possess the receptors for viral
attachment and penetration into the cells (33, 46, 47).
Thus, the blocking of viral propagation must be occurring at subsequent
steps within the rat cells. Identification of the blocking step and the
responsible host factor(s) could lead to the construction of transgenic
rats that express the critical human factor(s) and that are highly
susceptible to HTLV-1 infection. Such transgenic rats might be expected
to develop ATL- and HAM/TSP-like diseases that more closely
resemble the human diseases.
The first hint of a blocking step was a report that showed that the
viral mRNAs encoding Gag and Env proteins are produced at low levels in
rat cells despite the fact that the mRNA for the Tax/Rex protein is
abundant (28). This observation led us to hypothesize that
Rex may function poorly in rat cells. In this study, we have assessed
this hypothesis and found that rat CRM1 (rCRM1) is a major cause of the
poor activity of Rex in rat cells. Our results indicate that, unlike
hCRM1, rCRM1 does not support Rex function efficiently because of its
poor ability to induce Rex dimer formation. Both rCRM1 and hCRM1,
however, bind to Rex NES and support the export of the Rex protein with
similar efficiencies. These findings suggest that rCRM1 is a poor
cofactor for assisting Rex multimerization and that this may be
responsible for the poor replication of HTLV-1 in rat cells.
 |
MATERIALS AND METHODS |
Cloning and plasmid construction.
To construct pSR
rCRM1,
full-length rCRM1 cDNA was amplified from a rat heart marathon cDNA
library (Clontech) by PCR using primers 5'-AAG AAG GAG CAG TTG GTT CAA
TCT CTG GTA A-3' and 5'-CGG GGT ACC CCC AGC CAC AAA AAT GGG CAT GAA
G-3'. The PCR product was blunt-ended by Pfu polymerase,
digested with KpnI, and cloned into pSR
296
(47), which had been digested with PstI,
blunt-ended, and then digested with KpnI. The insert
sequence of the resulting construct was confirmed by DNA sequencing
using an Applied Biosystems 377 automated DNA sequencer.
To construct pGALrCRM1, the rcrm1 coding region was
amplified from pSR
rCRM1 by PCR with primer pair 5'-GGA AGA TCT ATG
CCA GCA ATT ATG ACA ATG TTA G-3' and 5'-AGG ACA AAC GCT GCA CAG GGA AA-3' and then blunt-ended by Pfu polymerase treatment,
digested with BglII, and cloned in-frame downstream of the
GAL4 DNA-binding domain in pSGGALVP (8), which had been
digested with BamHI, blunt-ended, and digested with
BglII.
To construct pDM128RxRE, the RxRE of the HTLV-1 genome
(42) was amplified by PCR using primers 5'-AAA CCG CTC GAG
CAC GCA TAT GGC TCA ATA AAC-3' and 5'-AAA CCG CTC GAG GGC GCA GAA CAG AAA A-3', digested with XhoI, and cloned into
XhoI-digested pDM128, whose expression of the
chloramphenicol acetyltransferase (CAT) protein is dependent on the
activity of human immunodeficiency virus type 1 Rev (18).
The amount of CAT protein expressed from pDM128RxRE reflects Rex activity.
Plasmids pSR
Rex, pSR
TAgRexM64, pCDM
-galactosidase
(pCDM
-gal), pGAL-, pGALRex, pRexVP, pSR
hCRM1, and pGALhCRM1 have
all been reported previously (11, 24).
Reporter plasmid for protein-protein interaction pG5BLuc, which harbors
the luciferase gene downstream of GAL4 binding sites, was kindly
donated by Y. Komoda (JAPAN TOBACCO, Inc.). This reporter plasmid
expresses the luciferase protein when the GAL-fused protein interacts
with the VP-fused protein.
Recombinant protein expression plasmids pET3dRanQ69L, pET3ahCRM1, and
pHisRex(g10) were kindly given by Y. Yoneda (16), D. Görlich (40), and J. Katahira.
Cell culture and transfection.
HeLa cells and rat REF52
cells were maintained in a 5% CO2 atmosphere at
37°C in Dulbecco modified Eagle medium that was supplemented with 10% fetal bovine serum. Transfection was carried out either with
DOTAP (Boehringer Mannheim) or Lipofectamine Plus (GIBCO-BRL Life
Technologies) reagents according to the respective manufacturer's instructions. Leptomycin B (LMB) (31) was administered
8 h posttransfection by replacing the medium with fresh medium
containing LMB at the proper concentration. The cells were harvested
24 h posttransfection. To normalize the transfection efficiency,
0.1 µg of pCDM
-gal was cotransfected in all samples and the total
amount of DNA in each experiment was kept constant by adding pSR
296.
All transfection experiments were performed in duplicate and were done
at least three times.
Measurement of Rex activity.
Various amounts of pSR
Rex
were transfected along with 0.5 µg of pDM128RxRE and 0.1 µg of
pCDM
-gal into HeLa or REF52 cells. In some experiments, pSR
hCRM1
or pSR
rCRM1 was cotransfected with or without LMB treatment. At
24 h posttransfection, the cells were lysed and the amount of CAT
was quantified using a CAT enzyme-linked immunosorbent assay kit
(Boehringer Mannheim) according to the manufacturer's instructions.
The
-galactosidase (
-Gal) activity was measured by standard
colorimetric methods. The ratio of CAT/
-Gal was calculated for each sample.
In vivo assay of protein-protein interaction.
Protein-protein interactions in mammalian cells were analyzed using the
mammalian two-hybrid system (11). The cells were transfected with 0.2 µg of the plasmid expressing the GAL fusion protein, 0.2 µg of the plasmid expressing the Rex-VP fusion protein, 0.2 µg of pG5BLuc as a reporter, and 0.1 µg of pCDM
-gal. In some experiments, pSR
hCRM1 or pSR
rCRM1 was cotransfected with or without LMB treatment. Luciferase (Luc) activity was quantified using the Steady-Glo Luc assay system (Promega) and the Wallac 1420 ARVOsx system. The ratio of Luc/
-Gal was calculated for each sample.
The activity of
-Gal in all samples was more than 3.0 × 10
3 U.
Immunofluorescence microscopy.
HeLa and REF52 cells were
transfected with 0.1 µg of pSR
Rex along with 0.25 µg of
pSR
hCRM1, pSR
rCRM1, or pSR
296. At 24 h posttransfection,
the cells were fixed with 2% paraformaldehyde and dissolved in
phosphate-buffered saline (PBS) for 15 min. After perforation with
0.1% NP-40 for 5 min, the cells were incubated with a rabbit anti-Rex
C-terminal antibody for 1 h at room temperature. After being
washed with PBS, the cells were stained with Cy3- or
rhodamine-B-conjugated goat anti-rabbit immunoglobulin G antibody for
1 h (Jackson ImmunoResearch or Biosource) as previously described (11). The stained cells were observed with an Axiovert 135 system (Carl Zeiss, Inc.).
Western blot analysis.
The proteins resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were
transferred to a nitrocellulose filter. A mouse anti-GAL4 monoclonal
antibody (Santa Cruz Biotechnology) and a rabbit anti-Rex C terminus
antibody (24) were used as primary antibodies to detect
GAL-fused proteins and the Rex protein, respectively. To compare the
expression levels of endogenous CRM1 in REF52 and HeLa cells,
approximately 20 µg of cell lysates was subjected to SDS-PAGE. The
blots were incubated with either of several primary antibodies, namely,
rabbit anti-CRM1 antiserum generated by immunization with the peptide
with the amino acid sequence
1024EFAGEDTSDLFLEEREIALR1043
(30), chicken anti-hCRM1 antiserum (specific for
1041ALRQADEEKHKRQMSVPG1058),
or rabbit anti-rCRM1 (specific for
1040TALRQAQEEKHKLQMSVP1057).
Horseradish peroxidase- or alkaline phosphatase-conjugated anti-immunoglobulin G antibodies (Promega) were used as secondary antibodies. Immunoreactive bands were visualized using ECL+plus (Amersham Pharmacia Biotech) followed by the LAS-1000 Plus system (Fujifilm) or BCIP (5-bromo-4-chloro-3-indolyl-phosphate)-nitroblue tetrazolium (NBT) solution.
Expression and purification of recombinant proteins.
The
recombinant RanQ69L protein was expressed in Escherichia
coli, purified, and then charged with GTP according to the method previously reported by Hieda et al. (16) with slight
modification. The MonoQ column (Amersham Pharmacia Biotech) was used
instead of a Fractogel EMDSO3-650(s) column.
Plasmid pHisRex(g10) expresses recombinant Rex protein with an
NH2-terminal His tag and a COOH-terminal gene10
peptide of
phage. Recombinant HisRex(g10) protein was expressed by
1 mM isopropyl-1-thio-
-D-galactopyranoside (IPTG)
for 15 h at 20oC in E. coli
strain BL21 (DE3) Gold (Stratagene). The E. coli cells were
lysed in buffer A (50 mM Tris-HCl [pH 8.0], 50 mM NaCl, 0.1 mg of
pefabloc/ml, 1 µg each of aprotinin, leupeptin, and pepstatin/ml)
containing 10 mM imidazole by sonication after two freeze-thaw cycles
and clarified by centrifugation (100,000 × g, 1 h). The supernatant was applied to a His-Trap
Ni+-chelating column (Amersham Pharmacia
Biotech). The recombinant protein, which was trapped in a chelating
column, was eluted with buffer A with 300 to 500 mM imidazole. The
pooled fraction containing the HisRex(g10) protein was subjected to
chromatography on a Hi-Trap Q column in a fast protein liquid
chromatography system (Amersham Pharmacia Biotech) equilibrated
with buffer A with 10 mM imidazole and separated with linear gradient
of buffer A containing 50 to 500 mM NaCl. The purified fraction was
desalted with a PD10 column (Amersham Pharmacia Biotech) equilibrated
with transport buffer (20 mM HEPES [pH 7.3], 110 mM potassium
acetate, 5 mM sodium acetate, 2 mM magnesium acetate, 0.5 mM EGTA, 2 mM
dithiothreitol, 1 µg each of aprotinin, leupeptin, and pepstatin/ml)
followed by concentration by ultrafiltration using Centricon YM 10 (Amicon).
Recombinant hCRM1 protein was expressed in E. coli strain
BL21 (DE3) Gold without addition of IPTG at 30°C. The E. coli cells were lysed in buffer B (50 mM Tris-HCl [pH 8.0], 50 mM NaCl, 1 mM MgCL2, 1 mM dithiothreitol, 1 µg
each of aprotinin, leupeptin, and pepstatin/ml) by freezing-thawing and
sonication. After centrifugation (100,000 × g, 1 h), the clarified lysate was applied to a Hi-Trap Q column equilibrated
with buffer B and separated with a linear gradient of buffer B
containing 50 to 500 mM NaCl. The fractions containing recombinant
hCRM1 protein were applied to Superdex 200 (Amersham Pharmacia Biotech)
equilibrated with the transport buffer and then concentrated by
ultrafiltration using Centricon YM 10.
Pull-down assay.
HeLa and REF52 cells (1.0 × 107) were scraped off, washed twice with 10 ml
of ice-cold PBS, and lysed in 200 µl of buffer C (50 mM HEPES [pH
7.9], 200 mM KCl, 2 mM 2-mercaptoethanol, 0.4% Tween 20) containing
0.4% skim milk by sonication. After centrifugation at 20,000 × g for 10 min, the supernatants were transferred to new
microcentrifuge tubes, and recombinant RanQ69L protein, GTP, and
MgCl2 were added at final concentrations of 2 µM, 2 mM, and 5 mM, respectively. One-tenth volume of the supernatant
was reserved as the input fraction. The remaining supernatants were
then incubated at 4°C for 2 h with recombinant HisRex(g10)
protein immobilized on chelating Sepharose. This conjugate was prepared
by incubating 30 µl of Ni+-chelating Sepharose
(reconstituted with 0.1 M NiSO4 solution and
Chelating Sepharose Fast Flow; Amersham Pharmacia Biotech) with 3 µg
of recombinant HisRex(g10) protein for 2 h at 4°C. The beads were washed three times with 1 ml of buffer C containing 5 mM
MgCl2 by low-speed centrifugation, and then
sample buffer was added to the beads (bound fraction). CRM1 proteins in
the input and bound fractions were analyzed by SDS-PAGE followed by Western blotting.
Coimmunoprecipitation assay.
HeLa and REF52 cells
(2.0 × 106) cultured on a
10-cm-diameter dish were transfected with GAL- and VP-fused
protein expression plasmids. To adjust the expression level of fusion
proteins, the following amounts of the expression plasmids were used:
1.5 µg of pGAL-Rex and pRex-VP (HeLa cells), 1.5 µg of pGAL-RexM90
and pRexM90-VP (HeLa cells), and 2 µg of pGAL-Rex and 4 µg of
pRex-VP (REF52 cells). At 48 h posttransfection, the cells were
lysed in 100 µl of buffer D (10 mM HEPES [pH 7.3], 150 mM NaCl, 3 mM MgCl2) by sonication. After centrifugation at
20,000 × g for 10 min, the supernatants were
transferred to new microcentrifuge tubes and recombinant RanQ69L
protein and GTP were added at final concentrations of 2 µM and 2 mM,
respectively. Recombinant hCRM1 protein (at a final concentration of
100 nM) was also added in some samples. One-tenth volume of the
supernatants was reserved as the input fraction. The remaining
supernatants were then incubated with 2 µg of rabbit anti-VP antibody
(Clontech) immobilized on 20 µl of protein G Sepharose at 4°C for
2 h. The beads were recovered by low-speed centrifugation and
washed four times with 1 ml of buffer D, and then sample buffer was
added to the beads (bound fraction). The fusion proteins in the input
and bound fractions were analyzed by SDS-PAGE followed by Western blotting.
 |
RESULTS |
Poor activity of Rex in rat cells.
Unspliced and incompletely
spliced viral mRNAs that, respectively, encode Gag and Env proteins are
produced at much lower levels in HTLV-1-infected rat cells than in
infected human cells despite the fact that Tax/Rex mRNA is abundantly
produced in both cell types (28). On the basis of these
observations, we hypothesized that Rex function may be impaired in rat
cells. To test Rex function in rat and human cells, we cotransfected
the rat REF52 and human HeLa cell lines with plasmids pDM128RxRE, a
reporter, pSR
Rex expressing the Rex protein, and pCDM
-gal.
Plasmid pDM128RxRE is a CAT-RxRE reporter construct that allows Rex
activity to be quantitated in a transient expression system (11,
18) because this plasmid expresses the CAT protein in a manner
that is dependent on Rex function. HeLa and REF52 were transfected with
various amounts of the Rex expression plasmid, and the levels of CAT
and Rex proteins in both cell types were evaluated by CAT enzyme-linked immunosorbent assay and Western blotting, respectively. Figure 1 shows that transfection of 0.05 µg of
pSR
Rex into HeLa cells enhanced production of CAT to a level about
17-fold more than that for the control sample without Rex. A
greater amount of pSR
Rex transfected had little effect although it
produced a greater amount of the Rex protein. In contrast, in the rat
cells Rex had almost no effect on CAT production in spite of an
expression level of Rex protein that was sufficiently high. Increasing
the amount of pSR
Rex transfected to 0.5 µg did not induce CAT
production in REF52 cells (data not shown). These results are
consistent with an earlier observation (28) and indicate
that Rex functions very poorly in rat cells.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Analysis of expression levels and activity of Rex in
HeLa and REF52 cells. HeLa and REF52 cells were transfected with the
indicated amounts of pSR Rex along with 0.5 µg of pDM128RxRE and
0.1 µg of pCDM -gal. A fraction of each sample was subjected to
Western blotting to examine Rex protein synthesis, while the other
fraction was used to measure Rex activity. The CAT/ -Gal ratios for
all samples were calculated. The ratio for the control sample (HeLa
cells transfected with pSR 296 instead of pSR Rex) was arbitrarily
set at 1. Error bars, standard deviations.
|
|
We also tested whether the human immunodeficiency virus type 1 Rev
protein, functional homologue to the Rex protein, works in REF52 cells
by using pDM128, which allows Rev activity to be quantitated
(18). Unlike the Rex protein, the Rev protein was able to
enhance the production of CAT protein in a manner dependent on the
levels of Rev expression in REF52 cells, although somewhat less
efficiently than in HeLa cells (data not shown). These observations indicate that Rex activity is limited in REF52 cells to a greater degree than that of Rev. Therefore we did not investigate Rev function
in rat cells anymore.
Cloning of rat CRM1 and expression.
The major cofactor for Rex
function is known to be CRM1, which plays crucial roles in both the
export and multimerization of the Rex protein (11). To
test whether the poor activity of Rex in rat cells may be due to the
weaker ability of rCRM1 than of hCRM1 to support Rex functions, we
cloned a cDNA encoding rCRM1. Sequence analysis revealed that the
nucleotide sequence of the rcrm1 cDNA was 89% identical to
that of hcrm1, while the predicted amino acid sequences were
97% identical, with only 24 aa being different (Fig.
2). In the next step, we generated
antibodies that differentially recognize rCRM1 and hCRM1 on the basis
of their carboxy-terminal amino acid sequences, where divergence between the two proteins is the highest. As shown in Fig.
3, Western blotting analyses demonstrated
that our antibodies, termed rabbit anti-rCRM1 and chicken anti-hCRM1
antiserum, could distinguish between the two CRM1 proteins. In
contrast, rabbit anti-CRM1 antiserum, elicited by a peptide whose
sequence corresponds to aa 1024 to 1043 (30), recognized
both rCRM1 and hCRM1. Similar blot patterns were observed for various
human (Jurkat cells, U251 cells, astrocytes, CD4+T cells, CD8+ T cells,
and macrophages) and rat (3Y1 cells) cell lines (data not shown). These
blots also clearly showed that the rat and human cells contained
similar amounts of CRM1.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of hCRM1 and rCRM1 amino acid sequences. The
amino acids of rCRM1 different from those of hCRM1 are shown under the
hCRM1 sequence in single-letter code.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 3.
Western blot analysis of endogenous hCRM1 and rCRM1
expression in HeLa and REF52 cells, respectively. Approximately 20 µg
of total cellular protein was subjected to SDS-PAGE. Rabbit anti-CRM1,
rabbit anti-rCRM1, or chicken anti-hCRM1 antiserum was used as the
primary antibodies.
|
|
Effect of rCRM1 on Rex function.
We investigated the
capacity of rCRM1 to support Rex function relative to that of hCRM1. We
measured Rex activity in REF52 cells cotransfected with pDM128RxRE,
pSR
Rex, and pCDM
-gal along with various amounts of the hCRM1 or
rCRM1 expression plasmid. Figure 4A shows
that hCRM1 augmented Rex activity in a dose-dependent manner, whereas
overexpression of rCRM1 had little effect. Western blotting of
transfected REF52 cells using rabbit anti-CRM1 antiserum showed that
nearly equivalent levels of CRM1 proteins are produced when the human
and rat crm1 genes are transfected in rat cells (Fig. 4B).
The fainter band seen in lane 1 indicates the endogenous rCRM1. Chicken
anti-hCRM1 antiserum could also detect the expression of hCRM1 in REF52
cells. These results indicate that rCRM1 can only weakly support Rex
function, suggesting that this may be the primary reason why Rex has
limited activity in rat cells. It is also possible, however, that there
may be another limiting factor that hampers the cofactor activity of
rCRM1 but not hCRM1 in rat cells. To exclude this possibility, we
tested the ability of rat and human CRM1 to support Rex function in
human cells. HeLa cells cotransfected with pSR
Rex, pDM128RxRE,
pCDM
-gal, and either pSR
hCRM1 or pSR
rCRM1 were placed in the
presence of LMB 8 h posttransfection. LMB specifically inactivates
CRM1 in HeLa cells (31), and thus it inhibits Rex
activity. We found, however, that when hCRM1 is overexpressed, Rex
activity is restored (Fig. 5A). In
contrast, rCRM1 did not restore Rex activity even though nearly
equivalent amounts of the two CRM1 proteins were produced exogenously,
as shown by Western blotting (Fig. 5B). Rabbit anti-rCRM1 antiserum
also demonstrated that rCRM1 is abundantly expressed in HeLa cells. It
is unlikely that rCRM1 is much more sensitive to LMB than hCRM1 (see
the description below; Table 1). Taken
together, these results indicate that rCRM1, unlike hCRM1, has only
very weak activity as a cofactor of Rex.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of overexpressing rat and human CRM1 on Rex
activity. (A) REF52 cells were transfected with 0.075 µg of pSR Rex
along with 0.5 µg of pDM128RxRE and 0.1 µg of pCDM -gal in
combination with various amounts of pSR hCRM1 ( ) or pSR rCRM1
( ). The CAT/ -Gal ratios of all samples were calculated. The ratio
of the sample transfected with pSR Rex in the absence of either the
hCRM1 or rCRM1 expression plasmid was arbitrarily set to 1. (B) CRM1
proteins produced in REF52 cells that were transfected with 0.3 µg of
either rCRM1 or hCRM1 expression plasmids (lane 1, pSR 296; lane 2, pSR hCRM1; lane 3, pSR rCRM1) were analyzed by Western blotting as
described in Materials and Methods.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 5.
Ability of hCRM1 and rCRM1 to support Rex function in
HeLa cells. (A) HeLa cells were transfected with 0.05 µg of
pSR Rex, 0.5 µg of pDM128RxRE, and 0.1 µg of pCDM -gal together
with various amounts of pSR hCRM1 or pSR rCRM1. At 8 h
posttransfection, the medium was replaced with medium containing LMB at
0.6 or 0.8 nM. At 24 h posttransfection, the cells were subjected
to CAT and -Gal measurement. The CAT/ -Gal ratios of all samples
were calculated. The ratio of the control sample transfected with
pSR Rex in the absence of either hCRM1 or rCRM1 expression plasmids
and in the absence of LMB was arbitrarily set to 1. The amounts of CAT
and the -Gal activity in the control sample were over 300 pg and
2.5 × 10 3 U, respectively. (B) CRM1 proteins
produced in HeLa cells transfected with 0.3 µg of each CRM1
expression plasmid (lane 1, pSR 296; lane 2, pSR hCRM1; lane 3, pSR rCRM1) were analyzed by Western blotting.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Effect of overexpression of hCRM1 and rCRM1 with or
without LMB on subcellular localization of Rex in HeLa and REF52
cellsa
|
|
Both rat and human CRM1 proteins can export Rex to the
cytoplasm.
As the data described above indicate that rCRM1 does
not help Rex export RxRE-bearing mRNA, we wondered whether rCRM1 was even able to export the Rex protein itself. Subcellular localization studies of Rex in REF52 and HeLa cells transfected with pSR
Rex, either alone or with plasmids expressing hCRM1 or rCRM1 (Fig. 6), showed that, in the absence of the
exogenously expressed CRM1 proteins, the Rex protein was predominantly
localized in the nucleus and nucleolus in HeLa cells (Fig. 6F). This
was true also for REF52 cells (Fig. 6A). However, when either hCRM1 or
rCRM1 was overexpressed by transfection of the relevant plasmids, the
Rex protein was mainly detected in the cytoplasm; that is probably due
to the enhanced transport to the cytoplasm by overexpression of its
export receptor, CRM1 (Fig. 6B, D, G, and I). This notion was supported
by the strong accumulation of the Rex protein in the nuclei in the
presence of LMB even under the condition of the overexpression of hCRM1
or rCRM1 (Fig. 6C, E, H, and J). Furthermore it is consistent with the
previous report showing cytoplasmic localization of Rex to be dependent
on the presence of an intact NES domain in Rex (11). Thus,
our data indicate that both rCRM1 and hCRM1 are able to support Rex
protein export. When the immunofluorescence microscopy was done
quantitatively, it appeared that the rat and human CRM1 proteins were
equivalent in their abilities to help the Rex protein move into the
cytoplasm (Table 1). When the cells overexpressing either hCRM1 or
rCRM1 were treated with LMB at various concentrations, the enhanced
transport of Rex to the cytoplasm, which was otherwise induced by
overexpressing CRM1s, was similarly inhibited in a manner dependent on
LMB concentration (Table 1). These results indicated that hCRM1 and
rCRM1 have similar sensitivities to LMB.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 6.
Subcellular localization of Rex in REF52 and HeLa cells
by immunofluorescence microscopy. REF52 and HeLa cells were transfected
with 0.1 µg of pSR Rex (A and F) or with 0.25 µg of either
pSR hCRM1 (B and G) or pSR rCRM1 (D and I). Some transfected
samples were treated with LMB at 2 nM for 2 h before fixation with
paraformaldehyde (C, E, H, and J). The procedure for immunofluorescence
analysis was done as indicated in Materials and Methods.
|
|
Rex protein-binding affinities of rCRM1 and hCRM1.
Next, we
examined the Rex protein-binding affinities of the rat and human CRM1s
in rat cells by the two-hybrid assay. Here rat and human CRM1 proteins
were expressed as GAL fusion proteins in the presence of the Rex-VP
fusion protein. The Luc/
-Gal ratios indicated that rCRM1 interacts
with Rex as efficiently as hCRM1 (Fig.
7A). Western blotting using a mouse
anti-GAL4 antibody indicated that the rat and human GAL-CRM1 fusion
proteins were expressed at equivalent levels (Fig. 7B). rCRM1 bound
much less efficiently to NES mutant RexM90 than to wild-type Rex,
indicating that, as for hCRM1, the binding of rCRM1 to Rex is
specifically mediated by the Rex NES (data not shown).



View larger version (90K):
[in this window]
[in a new window]
|
FIG. 7.
Interaction of Rex with either hCRM1 or rCRM1. (A) REF52
cells were transfected with the plasmid expressing either GAL-hCRM1 or
GAL-rCRM1 in combination with pRexVP, pG5BLuc, and pCDM -gal. The
Luc/ -Gal ratios of all samples were calculated. GAL-, plasmid
expressing only the GAL4 region, which was used as a negative control.
(B) Western blot of GAL-hCRM1 and GAL-rCRM1 proteins synthesized in
transfected REF52 cells. (C) Pull-down assay using recombinant Rex
protein. Purified His-Rex(g10) proteins immobilized on chelating
Sepharose were incubated with HeLa or REF52 cell extract in the absence
(lanes 2 and 4) or presence (lanes 3 and 5) of GTP-charged recombinant
RanQ69L protein. The sample of lane 1 contained neither cell lysate nor
recombinant RanQ69L proteins during incubation. The volume of the cell
extract subjected to the binding reaction was nine times of that of the
input fraction.
|
|
To ascertain the binding of Rex to each CRM1, a pull-down assay using a
recombinant Rex protein was done. As shown in Fig. 7C, Rex bound to
hCRM1 and rCRM1 with similar efficiencies in the presence of
GTP-charged RanQ69L protein, a GTPase-deficient Ran mutant. The
requirement for Ran-GTP guarantees specific binding of both hCRM1 and
rCRM1 to Rex since the trimeric complex of CRM1, leucine-rich NES, and
Ran-GTP has been well documented (7, 39, 45). These
results coincide with the results of the two-hybrid assay (Fig. 7A).
Together with the indirect immunofluorescence data described above
(Fig. 6 and Table 1), our data suggest that rCRM1 can bind to and
export Rex protein as efficiently as hCRM1 in rat cells.
The dominant-negative effect of rCRM1.
The facts that rCRM1 is
able to interact with the Rex protein but did not support its function
might suggest a dominant-negative effect of rCRM1 over hCRM1 in Rex
functioning. To assess this possibility, HeLa cells were transfected
with pSR
Rex along with various amounts of pSR
hCRM1 or
pSR
rCRM1. As expected, the activity of Rex was not affected by
overexpression of hCRM1. On the other hand, Rex activity was
significantly reduced by overexpression of rCRM1 in a dose-dependent
manner (Fig. 8). This result suggests that rCRM1 has dominant-negative phenotype and is one more piece of
evidence supporting the idea that rCRM1 hardly works as a cofactor of
Rex although rCRM1 can interact with the Rex protein similarly to
hCRM1.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 8.
The dominant-negative effect of rCRM1 on Rex activity in
HeLa cells. HeLa cells were transfected with 0.05 µg of pSR Rex,
0.5 µg of pDM128RxRE, and 0.1 µg of pCDM -gal together with
various amounts of pSR hCRM1 or pSR rCRM1. At 24 h
posttransfection, the cells were subjected to CAT and -Gal
measurement. The CAT/ -Gal ratios of all samples were calculated. The
ratio of the control sample transfected with pSR Rex in the absence
of either hCRM1 or rCRM1 expression plasmid was arbitrarily set to 1. The amounts of CAT and the -Gal activity in the control sample were
over 350 pg and 3.0 × 10 3 U, respectively.
|
|
rCRM1 does not support a Rex-Rex interaction.
It has been
reported that Rex has to multimerize on the cognate RNA before the
complex can be transported to the cytoplasm. This multimerization
depends on the ability of Rex proteins to form homodimers via
protein-protein interaction. We had previously reported that hCRM1
contributes to the Rex-Rex interaction (11). To evaluate
whether rCRM1 can similarly support the Rex-Rex interaction, a
two-hybrid assay wherein both Gal-Rex and Rex-VP fusion proteins were
coexpressed in REF52 cells was employed (Fig.
9). In the absence of the exogenously
expressed CRM1 protein, the extent of the Rex-Rex interaction was very
small because it was similar to that of the negative control in
which GAL- and Rex-VP were coexpressed (data not shown). But
overexpression of hCRM1 efficiently enhanced the Rex-Rex interaction.
However, when rCRM1 was overexpressed, the enhancement of Rex-Rex
interactions could hardly be detected. The overexpressed CRM1 proteins
in each sample were confirmed by Western blotting (data not shown).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 9.
Induction of Rex-Rex dimerization by hCRM1 but not rCRM1
in REF52 cells. REF52 cells were transfected with pGALRex, pRexVP,
pG5BLuc, and pCDM -gal in combination with various amounts of
pSR hCRM1 ( ) or pSR rCRM1 ( ). At 24 h posttransfection,
the cells were harvested to measure the luciferase and -Gal
activities. The Luc/ -Gal ratios of all samples were calculated.
|
|
As LMB has been reported to specifically inhibit CRM1 function
(31), we tested the effect of LMB on the Rex-Rex
interaction in HeLa cells. The Rex-Rex interaction in the presence of
0.4 nM LMB was reduced by 40% relative to the value in the absence of
LMB (Fig. 10), which confirms that Rex
dimerization requires hCRM1. We next examined whether Rex-Rex
interactions that had been inhibited by LMB could be restored by
overexpression of rCRM1 or hCRM1. We found that hCRM1 could almost
completely restore Rex-Rex interactions but that rCRM1 could not (Fig.
10). Similar results were obtained when 0.6 nM LMB was used (data not
shown). Thus, it appears that rCRM1 is unable to support the Rex-Rex
interaction.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 10.
Restoration of Rex-Rex dimerization in HeLa cells by
overexpression of hCRM1 but not rCRM1. HeLa cells were transfected with
pGALRex, pRexVP, pG5BLuc, and pCDM -gal in combination with 0.1 µg
of pSR hCRM1 or pSR rCRM1. At 8 h posttransfection, treatment
with 0.4 nM LMB commenced. At 24 h posttransfection, the cells
were harvested and the Luc/ -Gal ratios of all samples were
calculated.
|
|
To confirm the above results, the interaction between differently
tagged Rex proteins was examined by the coimmunoprecipitation method.
HeLa and REF52 cells were transfected with GAL-Rex and Rex-VP
expression plasmids. As a control, RexM90 fusion derivatives were used
since RexM90 could not form dimers, as judged by a two-hybrid assay
(11). The cell extracts were subjected to
immunoprecipitation with an anti-VP16 antibody in the presence of
GTP-charged RanQ69L, and the coprecipitated GAL-fused proteins were
evaluated by Western blotting. The recombinant RanQ69L protein was used
since it has been suggested that Rex-Rex dimerization requires the
interaction of Rex with CRM1 and, consequently, Ran-GTP. GAL-Rex was
coimmunoprecipitated with Rex-VP in HeLa cell lysate but not in REF52
cell lysate (Fig. 11, lanes 2 and 5).
In contrast, GAL-RexM90 was not coimmunoprecipitated with RexM90-VP
(Fig. 11, lane 3), consistent with our previous two-hybrid data
(11). Another multimerization-deficient mutant, RexM64,
was not coprecipitated as expected (data not shown). Addition of the
recombinant hCRM1 protein to REF52 cell lysate during incubation enhanced coimmunoprecipitation of GAL-Rex compared to that for the
sample without the recombinant hCRM1 protein (Fig. 11, lane 5 and 6).
These results indicate that the ability of rCRM1 to support the Rex-Rex
interaction is considerably less than that of hCRM1 although both CRM1s
can bind efficiently to the Rex protein. This property of rCRM1 may be
responsible for the inability of the Rex protein in rat cells to
transport gag/env mRNAs into the cytoplasm.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 11.
Rex-Rex dimerization analyzed by the
coimmunoprecipitation method. HeLa and REF52 cells were transfected
with the plasmids which express GAL-Rex and Rex-VP or their derivatives
as indicated. At 48 h posttransfection, the cells were harvested
and the supernatants were incubated with anti-VP antibodies immobilized
on protein-G Sepharose in the presence of GTP-charged recombinant
RanQ69L. The recombinant hCRM1 protein was added to the sample, which
was derived from the REF52 cells transfected with GAL-Rex and Rex-VP
(lane 6) during incubation. The volume of the cell extract subjected to
the coimmunoprecipitation reaction was nine times of that of input
fraction. Rabbit anti-Rex C terminus antibodies were used for Western
blotting.
|
|
 |
DISCUSSION |
In this study, we aimed to determine why HTLV-1 replicates so
poorly in rats. We particularly focused on Rex protein function in rat
cells because Koya et al. have reported that, although Tax/Rex-encoding
mRNA is abundant in rat cells, the viral mRNAs encoding Gag and Env
proteins are produced at low levels (28). We show here
that Rex functions very inefficiently in rat cells because rCRM1,
unlike hCRM1, works very poorly as a cofactor for Rex activity. We
found that rCRM1 binds to and exports the Rex protein into the
cytoplasm as efficiently as hCRM1 (Fig. 6 and 7 and Table 1),
indicating that rCRM1 may be able to act as an export receptor for
the Rex protein and other NES-bearing proteins. LMB sensitivities of
hCRM1 and rCRM1 seem to be quite similar (Fig. 6 and Table 1),
coincident with conservation of the amino acid sequence around the
cysteine residue at aa 528, which may be a binding site of LMB
(31) (Fig. 2). On the other hand, rCRM1 is unable to
induce Rex-Rex homodimer formation (Fig. 9 to 11), which is required
for Rex multimerization on target RNA (2) destined for
export to the cytoplasm. Thus, the limited ability of rCRM1 to act as a
cofactor for Rex may be responsible for the poor replication of HTLV-1
in rats. Our results suggest that better rat models of HTLV-1 infection
could be developed by constructing transgenic rats expressing hCRM1.
This notion is partly supported by our observation that, as shown in
Fig. 4A, overexpression of hCRM1 could restore Rex activity in rat
cells. Formal proof of this concept would be the observation that
HTLV-1 actually does replicate better in rat cells that express hCRM1.
However, a possible problem with such transgenic rat models may be that
the presence of rCRM1 in rat cells could have a dominant-negative
effect on hCRM1 because rCRM1 binds to Rex as efficiently as hCRM1
does. This dominant-negative effect on Rex activity was detected when rCRM1 was overexpressed in HeLa cells, although a relatively large amount of rCRM1 was required (Fig. 8). Thus, more investigation is
necessary to optimize the conditions under which Rex will fully function in rat cells.
With respect to the formation of the transport complex composed of
viral RNA, Rex, and possibly other cellular factors, we believe that
either a Rex-hCRM1-Ran-GTP complex initiates binding to the
high-affinity site contained in RxRE or that Rex binds to the
high-affinity site at the same time as it associates with hCRM1 with
the aid of Ran-GTP. Following this step, additional Rex molecules then
bind to the viral RNA through its nonspecific RNA-binding activity
(13), eventually provoking Rex polymerization along the
viral RNA transcript via its multimerization domain with the aid of
hCRM1. This process would allow a number of Rex proteins to cover the
RNA, thus increasing the number of hCRM1 molecules that associate with
the complex. The association of multiple CRM1 molecules may be
important to overcome the factors that retain RNAs in the nucleus
(34) and would allow the RNAs to pass efficiently through
nuclear pores.
Two possible mechanisms by which CRM1 induces Rex multimerization can
be envisaged. The association of CRM1 with the NES region of the Rex
protein may trigger a conformational change in Rex that leads directly
to its multimerization. Alternatively, the binding of CRM1 to the NES
may be necessary but not sufficient, and additional interactions
between Rex and CRM1 with or without the aid of another putative factor
may be required for multimerization. The second possibility is
supported by our observation that rCRM1 binds Rex as efficiently as
hCRM1 but does not support Rex multimerization, which indicates that
Rex multimerization induced by CRM1 is separable from the simple
binding of Rex NES to CRM1. We infer that hCRM1 may possess a domain
required for its additional interaction with Rex to induce the Rex-Rex
interaction. As rCRM1 differs from hCRM1 by only 24 aa, these two
proteins are particularly suitable for future research into the
structure-function relationships involved in Rex-Rex interaction
induced by CRM1.
Our observations underscore the importance of Rex multimerization in
RNA export. Rex-dependent RNA export is different from Rex protein
export in that Rex multimerization is essential for successful RNA
export. Multimerization may be a general feature of RNA-binding
proteins that are involved in RNA metabolism, since hnRNP A1, C1, E2,
I, K, and L proteins have all been reported to multimerize
(27). Although the role and mechanism of multimerization of these proteins have not been studied in detail, studies
investigating the multimerization of Rex may provide insights into
these phenomena.
We thank M. Yoshida for LMB and anti-CRM1 antiserum, T. Kanno for
REF52 cells, M. Komoda for pG5BLuc, Y. Yoneda for pET3dRanQ69L, D. Görlich for pET3ahCRM1, J. Katahira for HisRex(g10), K. Nishiike and F. Kokusen for excellent technical assistance, and Y. Okuda and A. Okuhara for manuscript preparation.
This investigation was supported by grants from the Ministry of Sports
and Culture (Japan) and the Ministry of Health and Welfare (Japan). Y. Hakata is a JSPS Research Fellow.
| 1.
|
Ballaun, C.,
G. K. Farrington,
M. Dobrovnik,
J. Rusche,
J. Hauber, and E. Bohnlein.
1991.
Functional analysis of human T-cell leukemia virus type I rex-response element: direct RNA binding of Rex protein correlates with in vivo activity.
J. Virol.
65:4408-4413[Abstract/Free Full Text].
|
| 2.
|
Bogerd, H., and W. C. Greene.
1993.
Dominant negative mutants of human T-cell leukemia virus type I Rex and human immunodeficiency virus type 1 Rev fail to multimerize in vivo.
J. Virol.
67:2496-2502[Abstract/Free Full Text].
|
| 3.
|
Bogerd, H. P.,
R. A. Fridell,
R. E. Benson,
J. Hua, and B. R. Cullen.
1996.
Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay.
Mol. Cell. Biol.
16:4207-4214[Abstract].
|
| 4.
|
Bogerd, H. P.,
G. L. Huckaby,
Y. F. Ahmed,
S. M. Hanly, and W. C. Greene.
1991.
The type I human T-cell leukemia virus (HTLV-I) Rex trans-activator binds directly to the HTLV-I Rex and the type 1 human immunodeficiency virus Rev RNA response elements.
Proc. Natl. Acad. Sci. USA
88:5704-5708[Abstract/Free Full Text].
|
| 5.
|
Bohnlein, E.,
J. Berger, and J. Hauber.
1991.
Functional mapping of the human immunodeficiency virus type 1 Rev RNA binding domain: new insights into the domain structure of Rev and Rex.
J. Virol.
65:7051-7055[Abstract/Free Full Text].
|
| 6.
|
Fang, J.,
S. Kushida,
R. Feng,
M. Tanaka,
T. Kawamura,
H. Abe,
N. Maeda,
M. Onobori,
M. Hori,
K. Uchida, and M. Miwa.
1998.
Transmission of human T-cell leukemia virus type 1 to mice.
J. Virol.
72:3952-3957[Abstract/Free Full Text].
|
| 7.
|
Fornerod, M.,
M. Ohno,
M. Yoshida, and I. W. Mattaj.
1997.
CRM1 is an export receptor for leucine-rich nuclear export signals.
Cell
90:1051-1060[CrossRef][Medline].
|
| 8.
|
Fujii, M.,
H. Tsuchiya,
T. Chuhjo,
T. Akizawa, and M. Seiki.
1992.
Interaction of HTLV-1 Tax1 with p67SRF causes the aberrant induction of cellular immediate early genes through CArG boxes.
Genes Dev.
6:2066-2076[Abstract/Free Full Text].
|
| 9.
|
Fukuda, M.,
S. Asano,
T. Nakamura,
M. Adachi,
M. Yoshida,
M. Yanagida, and E. Nishida.
1997.
CRM1 is responsible for intracellular transport mediated by the nuclear export signal.
Nature
390:308-311[CrossRef][Medline].
|
| 10.
|
Grassmann, R.,
S. Berchtold,
C. Aepinus,
C. Ballaun,
E. Boehnlein, and B. Fleckenstein.
1991.
In vitro binding of human T-cell leukemia virus rex proteins to the rex-response element of viral transcripts.
J. Virol.
65:3721-3727[Abstract/Free Full Text].
|
| 11.
|
Hakata, Y.,
T. Umemoto,
S. Matsushita, and H. Shida.
1998.
Involvement of human CRM1 (exportin 1) in the export and multimerization of the Rex protein of human T-cell leukemia virus type 1.
J. Virol.
72:6602-6607[Abstract/Free Full Text].
|
| 12.
|
Hanly, S. M.,
L. T. Rimsky,
M. H. Malim,
J. H. Kim,
J. Hauber,
M. Duc Dodon,
S. Y. Le,
J. V. Maizel,
B. R. Cullen, and W. C. Greene.
1989.
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.
Genes Dev.
3:1534-1544[Abstract/Free Full Text].
|
| 13.
|
Heaphy, S.,
C. Dingwall,
I. Ernberg,
M. J. Gait,
S. M. Green,
J. Karn,
A. D. Lowe,
M. Singh, and M. A. Skinner.
1990.
HIV-1 regulator of virion expression (Rev) protein binds to an RNA stem-loop structure located within the Rev response element region.
Cell
60:685-693[CrossRef][Medline].
|
| 14.
|
Heger, P.,
O. Rosorius,
C. Koch,
G. Casari,
R. Grassmann, and J. Hauber.
1998.
Multimer formation is not essential for nuclear export of human T-cell leukemia virus type 1 Rex trans-activator protein.
J. Virol.
72:8659-8668[Abstract/Free Full Text].
|
| 15.
|
Hidaka, M.,
J. Inoue,
M. Yoshida, and M. Seiki.
1988.
Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins.
EMBO J.
7:519-523[Medline].
|
| 16.
|
Hieda, M.,
T. Tachibana,
F. Yokoya,
S. Kose,
N. Imamoto, and Y. Yoneda.
1999.
A monoclonal antibody to the COOH-terminal acidic portion of ran inhibits both the recycling of ran and nuclear protein import in living cells.
J. Cell Biol.
144:645-655[Abstract/Free Full Text].
|
| 17.
|
Hinuma, Y.,
K. Nagata,
M. Hanaoka,
M. Nakai,
T. Matsumoto,
K. I. Kinoshita,
S. Shirakawa, and I. Miyoshi.
1981.
Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.
Proc. Natl. Acad. Sci. USA
78:6476-6480[Abstract/Free Full Text].
|
| 18.
|
Hope, T. J.,
X. J. Huang,
D. McDonald, and T. G. Parslow.
1990.
Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif.
Proc. Natl. Acad. Sci. USA
87:7787-7791[Abstract/Free Full Text].
|
| 19.
|
Ibuki, K.,
S. I. Funahashi,
H. Yamamoto,
M. Nakamura,
T. Igarashi,
T. Miura,
E. Ido,
M. Hayami, and H. Shida.
1997.
Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukemia virus type I envelope gene.
J. Gen. Virol.
78:147-152[Abstract].
|
| 20.
|
Inoue, J.,
M. Yoshida, and M. Seiki.
1987.
Transcriptional (p40x) and post-transcriptional (p27x-III) regulators are required for the expression and replication of human T-cell leukemia virus type I genes.
Proc. Natl. Acad. Sci. USA
84:3653-3657[Abstract/Free Full Text].
|
| 21.
|
Ishiguro, N.,
M. Abe,
K. Seto,
H. Sakurai,
H. Ikeda,
A. Wakisaka,
T. Togashi,
M. Tateno, and T. Yoshiki.
1992.
A rat model of human T lymphocyte virus type I (HTLV-I) infection. 1. Humoral antibody response, provirus integration, and HTLV-I-associated myelopathy/tropical spastic paraparesis-like myelopathy in seronegative HTLV-I carrier rats.
J. Exp. Med.
176:981-989[Abstract/Free Full Text].
|
| 22.
|
Jacobson, S.,
C. S. Raine,
E. S. Mingioli, and D. E. McFarlin.
1988.
Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis.
Nature
331:540-543[CrossRef][Medline].
|
| 23.
|
Kalyanaraman, V. S.,
M. G. Sarngadharan,
Y. Nakao,
Y. Ito,
T. Aoki, and R. C. Gallo.
1982.
Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan.
Proc. Natl. Acad. Sci. USA
79:1653-1657[Abstract/Free Full Text].
|
| 24.
|
Katahira, J.,
T. Ishizaki,
H. Sakai,
A. Adachi,
K. Yamamoto, and H. Shida.
1995.
Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans-dominantly by a Rex mutant deficient in RNA binding.
J. Virol.
69:3125-3133[Abstract].
|
| 25.
|
Kato, H.,
Y. Koya,
T. Ohashi,
S. Hanabuchi,
F. Takemura,
M. Fujii,
H. Tsujimoto,
A. Hasegawa, and M. Kannagi.
1998.
Oral administration of human T-cell leukemia virus type 1 induces immune unresponsiveness with persistent infection in adult rats.
J. Virol.
72:7289-7293[Abstract/Free Full Text].
|
| 26.
|
Kim, F. J.,
A. A. Beeche,
J. J. Hunter,
D. J. Chin, and T. J. Hope.
1996.
Characterization of the nuclear export signal of human T-cell lymphotropic virus type 1 Rex reveals that nuclear export is mediated by position-variable hydrophobic interactions.
Mol. Cell. Biol.
16:5147-5155[Abstract].
|
| 27.
|
Kim, J. H.,
B. Hahm,
Y. K. Kim,
M. Choi, and S. K. Jang.
2000.
Protein-protein interaction among hnRNPs shuttling between nucleus and cytoplasm.
J. Mol. Biol.
298:395-405[CrossRef][Medline].
|
| 28.
|
Koya, Y.,
T. Ohashi,
H. Kato,
S. Hanabuchi,
T. Tsukahara,
F. Takemura,
K. Etoh,
M. Matsuoka,
M. Fujii, and M. Kannagi.
1999.
Establishment of a seronegative human T-cell leukemia virus type 1 (HTLV-1) carrier state in rats inoculated with a syngeneic HTLV-1-immortalized T-cell line preferentially expressing Tax.
J. Virol.
73:6436-6443[Abstract/Free Full Text].
|
| 29.
|
Kubota, S.,
T. Nosaka,
B. R. Cullen,
M. Maki, and M. Hatanaka.
1991.
Effects of chimeric mutants of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex on nucleolar targeting signals.
J. Virol.
65:2452-2456[Abstract/Free Full Text].
|
| 30.
|
Kudo, N.,
S. Khochbin,
K. Nishi,
K. Kitano,
M. Yanagida,
M. Yoshida, and S. Horinouchi.
1997.
Molecular cloning and cell cycle-dependent expression of mammalian CRM1, a protein involved in nuclear export of proteins.
J. Biol. Chem.
272:29742-29751[Abstract/Free Full Text].
|
| 31.
|
Kudo, N.,
N. Matsumori,
H. Taoka,
D. Fujiwara,
E. P. Schreiner,
B. Wolff,
M. Yoshida, and S. Horinouchi.
1999.
Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region.
Proc. Natl. Acad. Sci. USA
96:9112-9117[Abstract/Free Full Text].
|
| 32.
|
Kushida, S.,
H. Mizusawa,
M. Matsumura,
H. Tanaka,
Y. Ami,
M. Hori,
K. Yagami,
T. Kameyama,
Y. Tanaka,
A. Yoshida,
H. Nyunoya,
K. Shimotono,
Y. Iwasaki,
K. Uchida, and M. Miwa.
1994.
High incidence of HAM/TSP-like symptoms in WKA rats after administration of human T-cell leukemia virus type 1-producing cells.
J. Virol.
68:7221-7226[Abstract/Free Full Text].
|
| 33.
|
Li, Q. X.,
D. Camerini,
Y. Xie,
M. Greenwald,
D. R. Kuritzkes, and I. S. Chen.
1996.
Syncytium formation by recombinant HTLV-II envelope glycoprotein.
Virology
218:279-284[CrossRef][Medline].
|
| 34.
|
Nakielny, S., and G. Dreyfuss.
1996.
The hnRNP C proteins contain a nuclear retention sequence that can override nuclear export signals.
J. Cell Biol.
134:1365-1373[Abstract/Free Full Text].
|
| 35.
|
Neville, M.,
F. Stutz,
L. Lee,
L. I. Davis, and M. Rosbash.
1997.
The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export.
Curr. Biol.
7:767-775[CrossRef][Medline].
|
| 36.
|
Nosaka, T.,
H. Siomi,
Y. Adachi,
M. Ishibashi,
S. Kubota,
M. Maki, and M. Hatanaka.
1989.
Nucleolar targeting signal of human T-cell leukemia virus type I rex-encoded protein is essential for cytoplasmic accumulation of unspliced viral mRNA.
Proc. Natl. Acad. Sci. USA
86:9798-9802[Abstract/Free Full Text].
|
| 37.
|
Ohashi, T.,
S. Hanabuchi,
H. Kato,
Y. Koya,
F. Takemura,
K. Hirokawa,
T. Yoshiki,
Y. Tanaka,
M. Fujii, and M. Kannagi.
1999.
Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus type 1-immortalized cells.
J. Virol.
73:6031-6040[Abstract/Free Full Text].
|
| 38.
|
Osame, M.,
K. Usuku,
S. Izumo,
N. Ijichi,
H. Amitani,
A. Igata,
M. Matsumoto, and M. Tara.
1986.
HTLV-I associated myelopathy, a new clinical entity.
Lancet
i:1031-1032.
|
| 39.
|
Ossareh-Nazari, B.,
F. Bachelerie, and C. Dargemont.
1997.
Evidence for a role of CRM1 in signal-mediated nuclear protein export.
Science
278:141-144[Abstract/Free Full Text].
|
| 40.
|
Paraskeva, E.,
E. Izaurralde,
F. R. Bischoff,
J. Huber,
U. Kutay,
E. Hartmann,
R. Lührmann, and D. Görlich.
1999.
CRM1-mediated recycling of snurportin 1 to the cytoplasm.
J. Cell Biol.
145:255-264[Abstract/Free Full Text].
|
| 41.
|
Rimsky, L.,
M. D. Dodon,
E. P. Dixon, and W. C. Greene.
1989.
Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator.
Nature
341:453-456[CrossRef][Medline].
|
| 42.
|
Seiki, M.,
J. Inoue,
M. Hidaka, and M. Yoshida.
1988.
Two cis-acting elements responsible for posttranscriptional trans-regulation of gene expression of human T-cell leukemia virus type I.
Proc. Natl. Acad. Sci. USA
85:7124-7128[Abstract/Free Full Text].
|
| 43.
|
Shida, H.,
T. Tochikura,
T. Sato,
T. Konno,
K. Hirayoshi,
M. Seki,
Y. Ito,
M. Hatanaka,
Y. Hinuma,
M. Sugimoto,
F.-T. Nishmaki,
T. Maruyama,
K. Miki,
K. Suzuki,
M. Morita,
H. Sashiyama,
N. Yoshimura, and M. Hayami.
1987.
Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection.
EMBO J.
6:3379-3384[Medline].
|
| 44.
|
Siomi, H.,
H. Shida,
S. H. Nam,
T. Nosaka,
M. Maki, and M. Hatanaka.
1988.
Sequence requirements for nucleolar localization of human T cell leukemia virus type I pX protein, which regulates viral RNA processing.
Cell
55:197-209[CrossRef][Medline].
|
| 45.
|
Stade, K.,
C. S. Ford,
C. Guthrie, and K. Weis.
1997.
Exportin 1 (Crm1p) is an essential nuclear export factor.
Cell
90:1041-1050[CrossRef][Medline].
|
| 46.
|
Sutton, R. E., and D. R. Littman.
1996.
Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system.
J. Virol.
70:7322-7326[Abstract/Free Full Text].
|
| 47.
|
Takebe, Y.,
M. Seiki,
J. Fujisawa,
P. Hoy,
K. Yokota,
K. Arai,
M. Yoshida, and N. Arai.
1988.
SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
Mol. Cell. Biol.
8:466-472[Abstract/Free Full Text].
|
| 48.
|
Tanaka, Y.,
R. Tanaka,
E. Terada,
Y. Koyanagi,
N. Miyano-Kurosaki,
N. Yamamoto,
E. Baba,
M. Nakamura, and H. Shida.
1994.
Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.
J. Virol.
68:6323-6331[Abstract/Free Full Text].
|
| 49.
|
Uemura, Y.,
S. Kotani,
S. Yoshimoto,
M. Fujishita,
S. Yano,
Y. Ohtsuki, and I. Miyoshi.
1986.
Oral transmission of human T-cell leukemia virus type I in the rabbit.
Jpn. J. Cancer Res.
77:970-973[Medline].
|
| 50.
|
Weichselbraun, I.,
J. Berger,
M. Dobrovnik,
H. Bogerd,
R. Grassmann,
W. C. Greene,
J. Hauber, and E. Bohnlein.
1992.
Dominant-negative mutants are clustered in a domain of the human T-cell leukemia virus type I Rex protein: implications for trans dominance.
J. Virol.
66:4540-4545[Abstract/Free Full Text].
|
| 51.
|
Yoshida, M.,
T. Suzuki,
J. Fujisawa, and H. Hirai.
1995.
HTLV-1 oncoprotein tax and cellular transcription factors.
Curr. Top. Microbiol. Immunol.
193:79-89[Medline].
|